Lipids, lipid-lowering therapy and diabetes complications;Lipides, traitements hypolipémiants et complications du diabète

Diabetes and Metabolism

Volumn 37, Issue 1, 2011, Pages 15-24

  Valensi, P ^a   Picard, S ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b Point Medical   (France)

Author keywords

Diabetes; Fenofibrate; Lipids; Nephropathy; Retinopathy; Review; Statins

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LOW LEVEL LASER THERAPY; MICROVASCULATURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM;

EID: 79951774866     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.10.001     Document Type: Review

References (123)

1. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57:995-1001. DCCT/EDIC Research Group.
2. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
3. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.
4. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 2009, 52:1219-1226.
5. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
6. Orchard T.J., Forrest K.Y., Kuller L.H., Becker D.J. Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001, 24:1053-1059.
7. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
8. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
9. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998, 21:160-178.
10. Jenkins A.J., Rowley K.G., Lyons T.J., Best J.D., Hill M.A., Klein R.L. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004, 10:3395-3418.
11. Ansquer J.C., Foucher C., Aubonnet P., Le Malicot K. Fibrates and microvascular complications in diabete-insight from the FIELD study. Curr Pharm Des 2009, 15:537-552.
12. http://www.eatlas.idf.org/.
13. Ray J.A., Valentine W.J., Secnik K., Oglesby A.K., Cordony A., Gordois A., et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005, 21:1617-1629.
14. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
15. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
16. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
18. Chalmers J., Cooper M.E. UKPDS and the legacy effect. N Engl J Med 2008, 359:1618-1620.
19. Shalitin S., Phillip M. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy. Diabetes Care 2008, 31 (Suppl.)(2):S121-S124.
20. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
21. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD. ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192.
22. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30:162-172.
23. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. Residual Risk Reduction Initiative (R3I). The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008, 5:319-335.
24. Fioretto P., Dodson P.M., Ziegler D., Rosenson R.S. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010, 6:19-25.
25. The ACCOR.D. Effect of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
26. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation endproducts: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
27. Orasanu G., Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009, 53(5 Suppl.):S35-S42.
28. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
29. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
30. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
31. Karalis D.G. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 2009, 84:345-352.
32. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
33. Cooney M.T., Dudina A., De Bacquer D., Wilhelmsen L., Sans S., Menotti A., et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009, 206:611-616.
34. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
35. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
36. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
37. Labreuche J., Deplanque D., Touboul P.J., Bruckert E., Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis. Systematic review and meta-regression analysis. Atherosclerosis 2010, 212:9-15.
38. Cirillo M., Lanti M.P., Menotti A., Laurenzi M., Mancini M., Zanchetti A., et al. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med 2008, 168:617-624.
39. Pun P.H., Smarz T.R., Honeycutt E.F., Shaw L.K., Al-Khatib S.M., Middleton J.P. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009, 76:652-658.
40. Bonnet F., Cooper M.E. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000, 26:254-264.
41. Gall M.A., Hougaard P., Borch-Johnsen K., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997, 314:783-788.
42. Hadjadj S., Duly-Bouhanick B., Bekherraz A., BrIdoux F., Gallois Y., Mauco G., et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004, 30:43-51.
43. Obermayr R.P., Temml C., Knechtelsdorfer M., Gutjahr G., Kletzmayr J., Heiss S., et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008, 23:1265-1273.
44. Satchell S.C., Tooke J.E. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008, 51:714-725.
45. Potenza M.A., Gagliardi S., Nacci C., Carratu' M.R., Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009, 16:94-112.
46. Miyata T., Ueda Y., Horie K., Nangaku M., Tanaka S., van Ypersele de Strihou C., et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998, 53:416-422.
47. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
48. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
49. Iacobini C., Menini S., Ricci C., Scipioni A., Sansoni V., Mazzitelli G., et al. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J Pathol 2009, 218:360-369.
50. Dominguez J.H., Tang N., Xu W., Evan A.P., Siakotos A.N., Agarwal R., et al. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 2000, 57:92-104.
51. Virella G., Carter R.E., Saad A., Crosswell E.G., Game B.A., Lopes-Virella M.F. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 2008, 127:394-400.
52. Klein B.E., Moss S.E., Klein R., Surawicz T.S. The Wisconsin epidemiologic study of diabetic retinopathy XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991, 98:1261-1265.
53. Miljanovic B., Glynn R.J., Nathan D.M., Manson J.E., Schaumberg D.A. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004, 53:2883-2892.
54. Chew E.Y., Klein M.L., Ferris F.L., Remaley N.A., Murphy R.P., et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996, 114:1079-1084.
55. Lyons T.J., Jenkins A.J., Zheng D., Lackland D.T., McGee D., Garvey W.T., et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004, 45:910-918.
56. Dodson P.M. Diabetic retinopathy: treatment and prevention. Diab Vasc Dis Res 2007, 4(3 Suppl.):S9-S11.
57. Wang X., Wang G., Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009, 148:883-889.
58. Alber H.F., Dulak J., Frick M., Dichtl W., Schwarzacher S.P., Pachinger O., et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 2002, 39:1951-1955.
59. Blann A.D., Belgore F.M., Constans J., Conri C., Lip G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160-1163.
60. Zimering M.B., Anderson R.J., Moritz T.E., Ge L. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the veterans affairs diabetes trial. Metabolism 2009, 58:393-400. Investigators for the VADT.
61. van Hecke M.V., Dekker J.M., Stehouwer C.D., Polak B.C., Fuller J.H., Sjolie A.K., et al. EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005, 28:1383-1389.
62. Juutilainen A., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007, 30:292-299.
63. Elliott J., Tesfaye S., Chaturvedi N., Gandhi R.A., Stevens L.K., Emery C., et al. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009, 32:1896-1900.
64. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
65. Hou R., Goldberg A.C., Tobin G.S. A case of severe neuropathy associated with hypertriglyceridemia. Endocr Pract 2008, 14:1020-1022.
66. Van Acker K., Bouhassira D., De Bacquer D., Weiss S., Matthys K., Raemen H., et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009, 35:206-213.
67. Wiggin T.D., Sullivan K.A., Pop-Busui R., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.
68. Virally M., Blicklé J.F., Girard J., Halimi S., Simon D., Guillausseau P.J. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007, 33:231-244.
69. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
70. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009, 11:89-94.
71. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
72. Remick J., Weintraub H., Setton R., Offenbacher J., Fisher E., Schwartzbard A. Fibrate therapy: an update. Cardiol Rev 2008, 16:129-141.
73. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
74. Robinson J.G. Should We Use PPAR agonists to reduce cardiovascular risk?. PPAR Res 2008, 2008:891425.
75. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
76. Saha S.A., Arora R.R. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010, 28:157-166.
77. Burgess D.C., Hunt D., Li L., Zannino D., Williamson E., Davis T.M., et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the fenofibrate intervention and event lowering in diabetes (FIELD) study. Eur Heart J 2010, 31:92-99.
78. Wotherspoon F., Laight D.W., Browne D.L., Turner C., Meeking D.R., Allard S.E., et al. Plasma homocysteine, oxidative stress and endothelial function in patients with type 1 diabetes mellitus and microalbuminuria. Diabet Med 2006, 23:1350-1356.
79. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
80. Jones P.H., Cusi K., Davidson M.H., Kelly M.T., Setze C.M., Thakker K., et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010, 10:73-84.
81. Tenenbaum A., Fisman E.Z., Motro M., Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20.
82. Scott R., O'Brien R., Fulcher G., Pardy C., D'Emden M., Tse D., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
83. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733-1737.
84. Rizzo M., Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007, 23:14-20.
85. Zambon A., Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007, 4(3 Suppl.):S15-S20.
86. Sacks F.M., Carey V.J., Fruchart J.C. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-694. [letter].
87. Canner P.L., Furberg C.D., McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am J Cardiol 2006, 97:477-479.
88. Sorrentino S.A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F.H., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
89. Hamilton SJ, Chew GT, Davis TM, Watts GF. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diab Vasc Dis Res 2010. [Epub ahead of print].
90. Miyashita Y., Endo K., Saiki A., Ban N., Nagumo A., Yamaguchi T., et al. Effect of Ezetimibe Monotherapy on Lipid Metabolism and Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Type 2 Diabetic Patients. J Atheroscler Thromb 2010, 17:1070-1076.
91. Danesh F.R., Kanwar Y.S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004, 18:805-815.
92. Rosenson R.S. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008, 6:1319-1330.
93. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008, 17:983-996.
94. Philis-Tsimikas A., Parthasarathy S., Picard S., Palinski W., Witztum J.L. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol 1995, 15:367-376.
95. Molitch M.E. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:1090-1099.
96. Strippoli G.F., Navaneethan S.D., Johnson D.W., Perkovic V., Pellegrini F., Nicolucci A., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651.
97. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
98. Douglas K., O'Malley P.G., Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117-124.
99. Sandhu S., Wiebe N., Fried L.F., Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006, 17:2006-2016.
100. Smulders Y.M., van Eeden A.E., Stehouwer C.D., Weijers R.N., Slaats E.H., Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. Eur J Clin Invest 1997, 27:997-1002.
101. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., Steiner G., Investigators D.A.I.S. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485-493.
102. Forsblom C., Hiukka A., Leinonen E.S., Sundvall J., Groop P.H., Taskinen M.R. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010, 33:215-220.
103. Broeders N., Knoop C., Antoine M., Tielemans C., Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 2000, 15:1993-1999.
104. Ansquer J.C., Dalton R.N., Caussé E., Crimet D., Le Malicot K., Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008, 51:904-913.
105. Goldberg R.B., Jacobson T.A. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008, 83:470-478.
106. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010, 61:58-61.
107. Cusick M., Chew E.Y., Chan C.C., Kruth H.S., Murphy R.P., Ferris F.L. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003, 110:2126-2133.
108. Bonetti P.O., Lerman L.O., Napoli C., Lerman A. Statin effects beyond lipid lowering - are they clinically relevant?. Eur Heart J 2003, 24:225-248.
109. Yamagishi S., Nakamura K., Matsui T., Sato T., Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 2006, 66:1019-1021.
110. Sen K., Misra A., Kumar A., Pandey R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002, 56:1-11.
111. Gupta A., Gupta V., Thapar S., Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004, 137:675-682.
112. Medina R.J., O'Neill C.L., Devine A.B., Gardiner T.A., Stitt A.W. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS ONE 2008, 3:e2584.
113. Klein R., Knudtson M.D., Klein B.E. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol 2007, 144:1-6.
114. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
115. Simó R., Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007, 370:1667-1668.
116. The ACCORD Study Group and ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
117. Klein B.E. Reduction in risk of progression of diabetic retinopathy. N Engl J Med 2010, 363:287-288.
118. Ismail-Beigi F., Craven T., Banerji M.A., Basile J., Calles J., Cohen R.M., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
119. Klein R. Intensive treatment of hyperglycaemia: ACCORD. Lancet 2010, 376:391-392.
120. Barakat M.R., Metelitsina T.I., DuPont J.C., Grunwald J.E. Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. Curr Eye Res 2006, 31:629-634.
121. Tarhzaoui K., Valensi P., Leger G., Cohen-Boulakia F., Lestrade R., Behar A. Rosuvastatin positively changes nerve electrophysiology in diabetic rats. Diabetes Metab Res Rev 2009, 25:272-278.
122. Davis T.M., Yeap B.B., Davis W.A., Bruce D.G. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008, 51:562-566.
123. Rajamani K., Colman P.G., Li L.P., Best J.D., Voysey M., D'Emden M.C., et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009, 373:1780-1788.